Skip to main
PTN
PTN logo

Palatin Technologies (PTN) Stock Forecast & Price Target

Palatin Technologies (PTN) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Palatin Technologies Inc. is poised for growth as it transitions focus toward the obesity market, supported by promising data demonstrating significant weight loss effects from its candidate PL7737 in preclinical studies. The initial addressable market size for its therapies suggests an attractive valuation, reinforcing the financial prospects associated with these developments. Furthermore, positive Phase 2 study results could validate the synergy of bremelanotide with GLP-1 receptor agonists, positioning Palatin favorably within a competitive therapeutic space with substantial unmet medical needs.

Bears say

Palatin Technologies Inc faces significant challenges that may negatively impact its stock outlook, primarily due to the risk of failed or inconclusive clinical trials, which could hinder the progression of its drug candidates. Additionally, the company's ability to secure adequate funding remains uncertain, which is crucial for advancing its development pipeline. These fundamental concerns regarding clinical efficacy and financial stability create a precarious environment for the company's long-term growth potential.

Palatin Technologies (PTN) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Palatin Technologies and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Palatin Technologies (PTN) Forecast

Analysts have given Palatin Technologies (PTN) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Palatin Technologies (PTN) has a Strong Buy consensus rating as of Jul 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Palatin Technologies (PTN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.